Serina Therapeutics

Yahoo Finance • 23 days ago

Serina Therapeutics Secures Up to $20 Million to Advance Registrational Trial of SER-252 in Parkinson’s Disease

Transaction structured to provide flexible funding to support Phase 1b registrational clinical study program in advanced Parkinson’s under the 505(b)(2) NDA pathwayEvaluating complementary funding including strategic equity and non-dilutiv... Full story

Yahoo Finance • 24 days ago

Serina Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

HUNTSVILLE, AL, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, announced that St... Full story

Yahoo Finance • last month

Serina Therapeutics Announces FDA Feedback Supports Registrational Trial Design of SER-252 in Advanced Parkinson’s Disease under 505(b)(2) NDA Pathway

- U.S. IND filing planned for Q4 2025 with U.S. enrollment expected to start in Q1 2026 - Patient dosing expected to begin in Australia in Q4 2025 HUNTSVILLE, AL, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (... Full story

Yahoo Finance • 2 months ago

Serina Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights

HUNTSVILLE, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company advancing its lead IND candidate, SER-252, for advanced Parkinson's disease, enabled by its p... Full story

Yahoo Finance • 2 months ago

Serina Therapeutics Advances POZ-VMAT2i into Development for Tardive Dyskinesia (TD)

- Novel once-weekly injectable VMAT2 inhibitor targets underserved patients with serious adherence and access challenges – - Potential expansion into Huntington’s chorea – an underserved indication with high need for long-acting VMAT2 the... Full story

Yahoo Finance • 2 months ago

Serina Therapeutics to Present at the BTIG Virtual Biotechnology Conference

HUNTSVILLE, AL, July 28, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today announced th... Full story

Yahoo Finance • 3 months ago

Serina Therapeutics CSO Moreadith sells $32,565 in shares

Serina Therapeutics, Inc. (NASDAQ:SER), a $53.7 million market cap biotech company, saw its Chief Scientific Officer Randall Moreadith sell 6,500 shares of common stock on July 14, 2025, for a total of $32,565. The shares were sold at pric... Full story

Yahoo Finance • 3 months ago

Serina Therapeutics to Present at FORCE Family Office Investor Webinar on June 26, 2025

How Parkinson’s affects million “ and why current treatments are not enoughContinuous dopaminergic stimulation (CDS): a next-gen approach to Parkinson’s careSerina’s drug candidate SER-252 is designed to deliver continuous symptom reliefJo... Full story